|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SDF4 |
Gene summary for SDF4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SDF4 | Gene ID | 51150 |
| Gene name | stromal cell derived factor 4 | |
| Gene Alias | Cab45 | |
| Cytomap | 1p36.33 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R084 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51150 | SDF4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.95e-04 | 2.05e-01 | 0.0155 |
| 51150 | SDF4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.20e-13 | 7.09e-01 | -0.1808 |
| 51150 | SDF4 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.78e-08 | 5.49e-01 | -0.0811 |
| 51150 | SDF4 | HTA11_78_2000001011 | Human | Colorectum | AD | 5.59e-10 | 5.97e-01 | -0.1088 |
| 51150 | SDF4 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.20e-29 | 8.41e-01 | -0.1954 |
| 51150 | SDF4 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.77e-08 | 1.21e+00 | -0.2602 |
| 51150 | SDF4 | HTA11_2112_2000001011 | Human | Colorectum | SER | 5.53e-03 | 8.60e-01 | -0.2196 |
| 51150 | SDF4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.08e-12 | 7.21e-01 | -0.1207 |
| 51150 | SDF4 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.39e-09 | 7.27e-01 | -0.1526 |
| 51150 | SDF4 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.76e-31 | 8.48e-01 | -0.1464 |
| 51150 | SDF4 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.78e-13 | 4.15e-01 | -0.1001 |
| 51150 | SDF4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.63e-21 | 8.59e-01 | -0.059 |
| 51150 | SDF4 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.06e-06 | 8.41e-01 | -0.1706 |
| 51150 | SDF4 | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.27e-06 | 6.19e-01 | -0.2061 |
| 51150 | SDF4 | HTA11_5216_2000001011 | Human | Colorectum | SER | 5.38e-05 | 7.53e-01 | -0.1462 |
| 51150 | SDF4 | HTA11_546_2000001011 | Human | Colorectum | AD | 3.66e-04 | 3.96e-01 | -0.0842 |
| 51150 | SDF4 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.00e-08 | 4.85e-01 | 0.096 |
| 51150 | SDF4 | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.46e-02 | 5.99e-01 | 0.0446 |
| 51150 | SDF4 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.20e-02 | 4.01e-01 | 0.0528 |
| 51150 | SDF4 | HTA11_10623_2000001011 | Human | Colorectum | AD | 7.04e-04 | 4.63e-01 | -0.0177 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00454441 | Liver | HCC | fat cell differentiation | 120/7958 | 229/18723 | 1.52e-03 | 8.05e-03 | 120 |
| GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
| GO:00454712 | Liver | HCC | response to ethanol | 72/7958 | 137/18723 | 1.10e-02 | 4.07e-02 | 72 |
| GO:00094114 | Oral cavity | OSCC | response to UV | 99/7305 | 149/18723 | 1.01e-11 | 3.70e-10 | 99 |
| GO:000931416 | Oral cavity | OSCC | response to radiation | 241/7305 | 456/18723 | 9.76e-10 | 2.40e-08 | 241 |
| GO:00454448 | Oral cavity | OSCC | fat cell differentiation | 120/7305 | 229/18723 | 2.48e-05 | 2.32e-04 | 120 |
| GO:00094164 | Oral cavity | OSCC | response to light stimulus | 159/7305 | 320/18723 | 5.98e-05 | 4.92e-04 | 159 |
| GO:009730519 | Oral cavity | OSCC | response to alcohol | 127/7305 | 253/18723 | 1.81e-04 | 1.24e-03 | 127 |
| GO:000941112 | Oral cavity | LP | response to UV | 63/4623 | 149/18723 | 1.74e-06 | 4.05e-05 | 63 |
| GO:000931417 | Oral cavity | LP | response to radiation | 155/4623 | 456/18723 | 4.12e-06 | 8.49e-05 | 155 |
| GO:0097305110 | Oral cavity | LP | response to alcohol | 80/4623 | 253/18723 | 7.24e-03 | 4.05e-02 | 80 |
| GO:00508087 | Prostate | BPH | synapse organization | 103/3107 | 426/18723 | 3.19e-05 | 3.61e-04 | 103 |
| GO:009730517 | Prostate | BPH | response to alcohol | 65/3107 | 253/18723 | 1.42e-04 | 1.27e-03 | 65 |
| GO:000931414 | Prostate | BPH | response to radiation | 105/3107 | 456/18723 | 2.07e-04 | 1.70e-03 | 105 |
| GO:00454447 | Prostate | BPH | fat cell differentiation | 59/3107 | 229/18723 | 2.60e-04 | 2.04e-03 | 59 |
| GO:00094113 | Prostate | BPH | response to UV | 37/3107 | 149/18723 | 6.40e-03 | 2.91e-02 | 37 |
| GO:00439547 | Prostate | BPH | cellular component maintenance | 18/3107 | 61/18723 | 8.45e-03 | 3.64e-02 | 18 |
| GO:004544414 | Prostate | Tumor | fat cell differentiation | 69/3246 | 229/18723 | 1.22e-06 | 2.28e-05 | 69 |
| GO:005080813 | Prostate | Tumor | synapse organization | 105/3246 | 426/18723 | 7.20e-05 | 7.62e-04 | 105 |
| GO:009730518 | Prostate | Tumor | response to alcohol | 68/3246 | 253/18723 | 9.02e-05 | 8.88e-04 | 68 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SDF4 | SNV | Missense_Mutation | novel | c.491N>C | p.Val164Ala | p.V164A | Q9BRK5 | protein_coding | tolerated(0.09) | benign(0.01) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SDF4 | SNV | Missense_Mutation | c.538G>C | p.Ala180Pro | p.A180P | Q9BRK5 | protein_coding | tolerated(0.12) | benign(0.006) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SDF4 | SNV | Missense_Mutation | c.202G>A | p.Glu68Lys | p.E68K | Q9BRK5 | protein_coding | deleterious(0.01) | possibly_damaging(0.833) | TCGA-E9-A1R0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| SDF4 | deletion | In_Frame_Del | novel | c.826_843delNNNNNNNNNNNNNNNNNN | p.Asp276_Asp281del | p.D276_D281del | Q9BRK5 | protein_coding | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SDF4 | SNV | Missense_Mutation | c.943G>A | p.Ala315Thr | p.A315T | Q9BRK5 | protein_coding | deleterious(0.02) | possibly_damaging(0.84) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SDF4 | SNV | Missense_Mutation | novel | c.268N>G | p.Phe90Val | p.F90V | Q9BRK5 | protein_coding | deleterious(0.03) | benign(0.313) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| SDF4 | SNV | Missense_Mutation | c.1063N>A | p.Ala355Thr | p.A355T | Q9BRK5 | protein_coding | deleterious(0) | possibly_damaging(0.895) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SDF4 | SNV | Missense_Mutation | rs778380110 | c.826G>A | p.Asp276Asn | p.D276N | Q9BRK5 | protein_coding | deleterious(0.01) | possibly_damaging(0.468) | TCGA-DM-A1HA-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| SDF4 | SNV | Missense_Mutation | novel | c.1055N>C | p.Val352Ala | p.V352A | Q9BRK5 | protein_coding | tolerated(0.2) | benign(0.01) | TCGA-A5-A2K7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
| SDF4 | SNV | Missense_Mutation | novel | c.910G>C | p.Glu304Gln | p.E304Q | Q9BRK5 | protein_coding | tolerated(0.1) | possibly_damaging(0.634) | TCGA-AJ-A2QM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51150 | SDF4 | NA | ETHANOL | ALCOHOL | 18355758 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |